Chardan Capital Reiterates Buy on Taysha Gene Therapies, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a price target of $5.
June 30, 2023 | 8:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Taysha Gene Therapies and maintained a price target of $5.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Taysha Gene Therapies. The maintained price target of $5 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100